"Brain Fog": The liver and brain are closely linked
Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
New patients should have an informed discussion with their doctor about the potential risks and benefits before starting semaglutide
Common medication triggers include antidepressants (particularly SSRIs and SNRIs), antihistamines, dopamine antagonists, and some antipsychotics
Comforting to know
11 The results seen in studies where BCAAs do reduce muscle soreness may be attributable to the fact that the consumption of protein prior to a workout can increase the amount of amino acids in the amino acid pool within the muscles, which can help to reduce the amount of muscle protein breakdown throughout a session
